ISPE Announces Next Steps As Nancy Berg Completes Term As CEO At End Of 2014
1/30/2014 10:57:24 AM
(TAMPA, Fla., USA, 30 January 2014) -- ISPE announced today that CEO Nancy Berg will leave the Society when her three year contract is completed at the end of 2014.
During her tenure with ISPE, Berg has been responsible for transformational change at ISPE, the world’s largest professional society fostering dialog and education on technical, scientific and regulatory best practices in the pharmaceutical and biotech industries. Berg was the architect of the Society’s ongoing Strategic Plan, focusing ISPE’s energies and expertise on high-value, ground-breaking initiatives related to drug shortages, quality metrics, global manufacturing quality, facility and supply chain issues and patient experiences in clinical trials. She has been instrumental in creating synergies between pharmaceutical industry stakeholders, bringing together diverse groups of professionals, regulators, and partner organizations to work on issues of shared concern. Berg’s work with the US Food and Drug Administration (FDA) and ISPE’s Drug Shortages Initiative is particularly noteworthy; in one project, she led teams of ISPE Members to complete groundbreaking research recently cited by FDA in its strategic plan and in senior official Congressional testimony.
Under Berg’s leadership, ISPE has also moved to strengthen its internal operations. The organization introduced a strategic redirection of focus in Europe and Asia, while in North America the Society plans to establish in 2014 an office in Washington, D.C. in addition to its headquarters in Tampa, Fla. Berg has been catalytic in evolving ISPE’s visibility and in building more contemporary business operations, streamlining governance processes and developing new revenue sources. The inaugural Pharma EXPO tradeshow (3 – 5 November 2014, Chicago), an event for the pharmaceutical industry managed in partnership with PMMI, was developed and launched on Berg’s watch.
Berg’s contributions to ISPE reflect her deep technical association experience involving strategic repositioning and growth, organizational integration and strong business acumen. “ISPE is poised to build on many of the successes of the past few years and continue a tradition of leadership now embedded in its philosophy,” Berg said. “With the foundation laid, a committed ISPE Board of Directors and a new transition plan in place, the stage is set for continued success under a new staff leader and beyond.”
Working through the end of 2014, Berg will continue to strengthen the organization, support the Board of Directors as it identifies a new CEO, and establish ISPE’s Washington office. “ISPE appreciates the strategic and directional work contributed by Nancy Berg. Her efforts have established an essential foundation for ensuring ISPE is a dynamic and relevant driver of value for its Members and the pharmaceutical industry,” says Damian Greene, 2014 Chair of ISPE’s International Board of Directors and Global Network Strategy Lead, Global Manufacturing and Supply at Zoetis, Brussels, Belgium.
The search for ISPE’s CEO is being conducted by Pamela Kaul, President, Association Strategies, Inc. Details regarding the search will soon be posted on ASI’s website: www.assnstrategies.com
ISPE, the International Society for Pharmaceutical Engineering, is the world’s largest not-for-profit association serving its Members through leading scientific, technical and regulatory advancement throughout the pharmaceutical lifecycle. The 20,000 Members of ISPE are building solutions in the development and manufacture of safe and effective pharmaceutical and biologic medicines and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters in Tampa, Florida, USA and offices in Shanghai, China and Frankfurt, Germany. Visit www.ISPE.org for more information.
For more information, contact:
ISPE Marketing Communications Manager
1-813-960-2105, ext. 277
Help employers find you! Check out all the jobs and post your resume.
comments powered by